Clinical Trial Update: Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies [Phase 1]

View source ↗

Summary

This Phase 1 trial of alisertib in combination with TAK-228 for HPV-associated malignancies has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Neoplasms
• Female Genital System Neoplasms
• Lip Oral Cavity and Pharynx Neoplasms
• Male Genital System Neoplasms

Drugs mentioned

• Alisertib (alisertib)
• Sapanisertib (sapanisertib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs | Phase 1 | Status: WITHDRAWN